Emmanouella Michaela Xanthopoulou

Emmanouella Michaela Xanthopoulou

Auto-generated profile, based on publicly available information

Emmanouella Michaela Xanthopoulou

Division of Medical Systems Bioengineering, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
IJInger Johansson
Inger Johansson
EXEmmanouella M. Xanthopoulou
Emmanouella M. Xanthopoulou
YZYitian Zhou
Yitian Zhou
ASAnabel Sanchez‐Spitman
Anabel Sanchez‐Spitman
MLMaaike van der Lee
Maaike van der Lee
MIMagnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
The polymorphic CYP2D6 enzyme plays a pivotal role in the metabolism of approximately 25% of clinically prescribed drugs. However, the impact of specific genetic variants on the interindividual variability in CYP2D6‐mediated drug metabolism remains insufficiently quantified. This translational study sought to address this gap by analyzing the genotypes and phenotypes of patients in two large clinical cohorts, focusing on the metabolism of the CYP2D6 substrates risperidone and desmethyltamoxifen. The analysis incorporated novel polymorphic haplotypes and substrate‐specific differences among the CYP2D6.1, CYP2D6.2, and CYP2D6.35 enzyme variants. The study revealed that CYP2D6.2 and CYP2D6.35 exhibit reduced metabolic capacity for these substrates, both in vivo and in an in vitro expression model. This was evidenced by decreased catalytic turnover (Kcat), decreased substrate affinity, and altered substrate docking. Furthermore, novel polymorphic haplotypes on the CYP2D6*1, CYP2D6*2, and CYP2D6*35 backgrounds were identified, each associated with a 30–40% increase in CYP2D6 activity. Incorporating these findings into prediction equations significantly improved the genetic prediction accuracy (R2) for CYP2D6‐mediated metabolism of desmethyltamoxifen from 59% to 71% and risperidone, also metabolized by CYP3A4, from 42% to 46%. These results highlight the importance of accounting for drug‐specific interactions with enzyme variants and integrating distinct polymorphic haplotypes into CYP pharmacogenomic models and guidelines for better translation into clinical practice.

9 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
LVLorenzo Vaccaro
Lorenzo Vaccaro
RSRosa De Santis
Rosa De Santis
FPFrancesco Panariello
Francesco Panariello
AGAntonio Grimaldi
Antonio Grimaldi
GGGennaro Gandolfo
Gennaro Gandolfo
DCDavide Cacchiarelli
Davide Cacchiarelli
Predicting the pathogenic effect of rare genetic variants is significantly hampered by the limited cohort of diagnosed patients and the difficulty in functionally evaluating the effect of existing and novel variants. To address this issue, we leveraged a protein Multiplexed Assay of Variants Effect (MAVE) to functionally assess the effect of ~ 2200 missense variants of the TP63 gene, some of which cause autosomal dominant developmental disorders. The activity of each variant was measured using an optimized fibroblast-to-keratinocyte conversion protocol, and a subset of mutants was validated through multiple orthogonal biochemical and genomics functional assays to assess consistency and robustness. To systematically expand MAVEs beyond predefined assay, we here introduce SCRAMseq (Single Cell RNAseq Associated with MAVEs by sequencing). This generalizable platform leverages full-length scRNAseq for high-throughput, single-cell genotype-to-phenotype mapping. We validate SCRAMseq across different experimental and genetic contexts to demonstrate its reproducibility and accuracy. SCRAMseq provides a robust and versatile workflow poised to accelerate the discovery and dissection of gene variant effects on any potential disease-driving pathway, thereby significantly broadening MAVEs applicability to virtually any possible disease-driving gene.